Janis Naeve
Partner at Cota Capital
Janis Naeve
Partner at Cota Capital
San Francisco, California
Overview
Work Experience
Partner
2022 - Current
Advisory Board Member
2024
AI-SDM is newly formed an interdisciplinary research institute funded by NSF to harness the power of AI and social sciences to empower decision-makers with tools that augment human judgment in complex, time-sensitive situations. AI-SDM at CMU collaborates with a diverse network of partners, including academic institutions, government agencies, and non-profit organizations, to develop and deploy impactful solutions that account for risk, trust, and equity in decision-making.
Board Observer
2022
Excision BioTherapeutics, Inc. is a clinical-stage biotechnology company developing CRISPR-based therapies as potential cures for viral infectious diseases.
Board Member
2022
Mission Bio is a leading life science company, specializing in the advancement of single-cell DNA and multiomic analysis for precision medicine, providing advanced tools and analytics for cell and gene therapies.
Board Member
2022
Algen, spun out of Jennifer Doudn'as lab is a platform therapeutics and drug discovery company using the world’s leading CRISPR and AI to uncover disease-driving RNA messages to find treatments for cancer, inflammation and other diseases.
Board Member
2022
Probius, spun out of Stanford, is a deep-tech company bridging the data gap between biology and AI by combining physics, mathematics, and biological data into their bioanalytical platform, Quantum Electrochemical Spectroscopy (QES) which translates a sample aliquot into a high-dimensional phenotypic signature, a digital twin, that can be re-analyzed and redefined in the cloud.
Board Observer
2022
CellFE has developed a scalable, high throughput microfluidic device for the efficient delivery of gene-editing molecules into cells enabling cell and gene therapies.
Board Member
2022 - 2023
Miroculus applied microfluidics in designing intuitive and flexible platforms based on its patented technology, simplifying complicated Next Generation sequencing protocols. Company was acquired by Integra Biosciences in March 2023
KidneyX Steering Committee
2022 - 2022
The Fund@Caltech Advisory Committee
2020 - 2022